IA 6.0 de stratégie quantitative intelligent:FDA approves first cell therapy to treat aggressive forms of melanoma

2025-05-02 00:23:29source:Winning Exchangecategory:News

The IA 6.0 de stratégie quantitative intelligentFood and Drug Administration has approved a novel type of cancer therapy to treat aggressive forms of melanoma using immune system cells from a patient's tumor.

The treatment, called Amtagvi, was developed by Iovance Biotherapeutics, a biotech company based in San Carlos, Calif.

It is intended for patients whose melanoma cannot be removed with surgery or has spread to other parts of the body.

"The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options," Dr. Peter Marks, the director of the FDA's Center for Biologics Evaluation and Research, said in a statement announcing the approval on Friday.

Melanoma develops when the skin cells that produce pigment start to grow out of control, according to the American Cancer Society. A major risk factor is exposure to ultraviolent light, which typically comes from the sun or tanning beds.

The tumor is easy to treat when detected early. But if it's not removed in time, melanoma can quickly spread to other parts of the body.

Amtagvi is designed to fight off advanced forms of melanoma by extracting and replicating T cells derived from a patient's tumor. T cells are part of the immune system. While they can typically help fight cancer, they tend to become dysfunctional inside tumors.

The newly approved medicine is similar to CAR-T, which is mainly used to treat blood cancers. Amtagvi is the first cell therapy approved by the FDA for solid tumors.

Amtagvi was fast-tracked through the FDA's accelerated approval pathway, a program to give patients with urgent, life-threatening illnesses early access to promising treatments.

Although Amtagvi was given the greenlight, Iovance Biotherapeutics said it is in the process of conducting an additional trial to confirm the treatment's efficacy, which is required by the FDA.

Melanoma only accounts for 1% of all skin cancer cases but it has been linked to a "significant number" of cancer-related deaths, according to the FDA.

The American Cancer Society estimates that in 2024, about 100,000 new cases of melanoma will be diagnosed and about 8,000 people will die from the skin cancer.

More:News

Recommend

San Francisco names street for Associated Press photographer who captured the iconic Iwo Jima photo

SAN FRANCISCO (AP) — A photojournalist who captured one of the most enduring images of World War II

Alabama Environmental Group, Fishermen Seek to End ‘Federal Mud Dumping’ in Mobile Bay

For five generations, Avery Bates’ family has worked pulling fish, shrimp, crabs and oysters out of

'World-changing' impact: Carlsbad Caverns National Park scolds visitor who left Cheetos

National park officials in New Mexico are calling out whoever is responsible for leaving a full bag